Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression

IMPORTANCE: Immunomodulatory anticancer drugs, such as the anti–programmed death-1 drug pembrolizumab, have shown promising results in trials, and more patients will receive such treatments. Little is known about cutaneous adverse events (AEs) caused by these drugs and their possible correlation wit...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:JAMA Dermatol
Autores principales: Sanlorenzo, Martina, Vujic, Igor, Daud, Adil, Algazi, Alain, Gubens, Matthew, Luna, Sara Alcántara, Lin, Kevin, Quaglino, Pietro, Rappersberger, Klemens, Ortiz-Urda, Susana
Formato: Artigo
Lenguaje:Inglês
Publicado: 2015
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5061067/
https://ncbi.nlm.nih.gov/pubmed/26222619
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamadermatol.2015.1916
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares